A phase 2 study reported efficacy for the tislelizumab plus lenvatinib combination in advanced fumarate hydratase-deficient renal cell carcinoma. The trial showed high objective response rates, reinforcing the strategy’s potential in a genomically defined rare subtype. Because FH-deficient RCC is difficult to treat and typically has limited trial-ready populations, the results are likely to influence both biomarker-driven development and future selection of comparable combination arms for other metabolically defined kidney tumors.
Get the Daily Brief